Nanobiotix Shares Surge 4.47% Mid-Session, Boosted by New Analyst Recommendation

Current Session Performance and Historical Growth

Nanobiotix's stock is currently up by 4.47% this Wednesday mid-session, priced at 19.16 euros compared to 18.34 euros at the previous day’s close. This movement occurs in a context of moderate volumes with only 0.27% of the capital traded. Over the past week, the French biotech's stock has already recorded an impressive performance of 9.11%, confirming the upward momentum that has been building for several weeks. Over three months, the stock has risen by 143.1%, while on an annual scale, it has soared by 519.7%, significantly outperforming the entire Parisian market. This exceptional trajectory is due to the continuous advancements in the company’s clinical pipeline, particularly in the development of its flagship candidate NBTXR3 in partnership with Johnson & Johnson. The stock is now fluctuating between a support level at 15.52 euros and a technical resistance at 19.56 euros, the latter being a major psychological threshold that the price is gradually approaching.

Anticipated Clinical Updates for NBTXR3

Nanobiotix is expected to provide several clinical data updates for NBTXR3 in 2026, which reinforces investor interest in this high-potential biotechnological stock.

Technical Analysis and Market Indicators

From a technical standpoint, the RSI is positioned at 48, a perfectly neutral level indicating that the stock is neither in an overbought nor oversold zone, thus allowing room for movement in either direction. This indicator suggests that the recent progress is sustainable without immediate speculative excess. The price is slightly above its 50-day moving average established at 18.66 euros, confirming the solidity of the medium-term trend. The significant gap with the 200-day moving average, which stands at 8.46 euros, materializes the spectacular acceleration of the stock since the beginning of the year. The MACD presents an encouraging setup with a positive histogram at 0.06, the MACD line at 0.05 is above the signal line at 0.00, signaling potential for continuation of the bullish movement in the short term. Volatility remains measured at 15.54% over a month, a relatively contained level for a biotechnological stock in clinical development phase. The Bollinger Bands frame the price between 17.05 euros and 19.25 euros, with the stock trading in the upper part of this channel, demonstrating maintained buying pressure. Furthermore, Goldman Sachs declared on December 2 that it had crossed below the 5% threshold of Nanobiotix's capital on November 26, a notable shareholder movement following the strong appreciation of the stock.